|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Esmolol#Clinical Studies]] |
| {{Esmolol}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
| | |
| ==Clinical Studies==
| |
| | |
| ===Supraventricular Tachycardia===
| |
| | |
| In two multicenter, randomized, double-blind, controlled comparisons of BREVIBLOC injection with placebo and [[propranolol]], maintenance doses of 50 to 300 mcg/kg/min of BREVIBLOC were found to be more effective than placebo and about as effective as [[propranolol]], 3-6 mg given by bolus injections, in the treatment of [[supraventricular tachycardia]], principally [[atrial fibrillation]] and [[atrial flutter]]. The majority of these patients developed their [[arrhythmias]] postoperatively. About 60-70% of the patients treated with BREVIBLOC developed either a 20% reduction in heart rate, a decrease in heart rate to less than 100 bpm, or, rarely, conversion to normal sinus rhythm and about 95% of these patients did so at a dosage of 200 mcg/kg/min or less. The average effective dosage of BREVIBLOC was approximately 100 mcg/kg/min in the two studies. Other multicenter baseline-controlled studies gave similar results. In the comparison with [[propranolol]], about 50% of patients in both the BREVIBLOC and [[propranolol]] groups were on concomitant [[digoxin]]. Response rates were slightly higher with both [[beta blocker]]s in the digoxin-treated patients.
| |
| | |
| In all studies significant decreases of blood pressure occurred in 20-50% of patients, identified either as adverse reaction reports by investigators, or by observation of systolic pressure less than 90 mmHg or diastolic pressure less than 50 mmHg. The [[hypotension]] was symptomatic (mainly [[hyperhidrosis]] or [[dizziness]]) in about 12% of patients, and therapy was discontinued in about 11% of patients, about half of whom were symptomatic. Hypotension was more common with BREVIBLOC (53%) than with [[propranolol]] (17%). The [[hypotension]] was rapidly reversible with decreased infusion rate or after discontinuation of therapy with BREVIBLOC. For both BREVIBLOC and propranolol, [[hypotension]] was reported less frequently in patients receiving concomitant digoxin.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = BREVIBLOC (ESMOLOL HYDROCHLORIDE) INJECTION [BAXTER HEALTHCARE CORPORATION] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=595cc3d5-1306-4828-aefa-5595219ffd62 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
|
| |
|
| | [[Category:Beta blockers]] |
| | [[Category:Cardiovascular Drugs]] |
| [[Category:Drugs]] | | [[Category:Drugs]] |